UNRESECTABLE ENDOMETRIAL CARCINOMA
Clinical trials for UNRESECTABLE ENDOMETRIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new UNRESECTABLE ENDOMETRIAL CARCINOMA trials appear
Sign up with your email to follow new studies for UNRESECTABLE ENDOMETRIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Custom cancer vaccine designed to train your own immune system
Disease control Recruiting nowThis study is testing a new, personalized vaccine designed to teach the body's immune system to recognize and attack a patient's specific cancer. It is being given alongside an existing immunotherapy drug (pembrolizumab) to adults with advanced solid tumors that have spread. The …
Matched conditions: UNRESECTABLE ENDOMETRIAL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 02, 2026 14:58 UTC
-
Scientists test Triple-Threat attack on Tough-to-Treat uterine cancer
Disease control Recruiting nowThis early-stage study is testing the safety of combining two cancer drugs (lenvatinib and pembrolizumab) with a short, intense course of pelvic radiation. The goal is to see if this three-part approach is safe and tolerable for people with a specific type of recurrent or inopera…
Matched conditions: UNRESECTABLE ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: Aaron Wolfson • Aim: Disease control
Last updated Mar 31, 2026 12:11 UTC
-
Scientists test 'One-Two Punch' against Tough-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing the safety and best dose of a new two-drug combination for people with advanced solid tumors that have a specific marker called HER2. The treatment pairs an existing targeted cancer drug with a new pill that aims to block cancer cells' ability to…
Matched conditions: UNRESECTABLE ENDOMETRIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC